orchard
Jul 16, 2020
Orchard licenses gene therapy tech from GSK; Glympse raises $46M; FDA voted to recommend Terlipressin; Breast Cancer research update
Orchard licenses the gene therapy technology from GlaxoSmithKline Orchard Therapeutics has permitted lentiviral stable cell line technology from GlaxoSmithKline for its use in hematopoietic stem cell gene therapies. GSK filed for patents on the tech before selling its rare disease gene therapy portfolio to...
Read More...
Aug 16, 2018
The Business Cocktail(Therapeutics)
Blueberry Therapeutics reels in USD 12.7 Million in series B funding for fungal infections. U.K.based, Blueberry Therapeutics successfully bagged a funding of USD 12.7 million in series B funding. The funding will help the company to advance its nanomedicine candidate, BB2603 for two fungal infections namely- Ath...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
